The agreement stipulates a minimum three-year partnership between EDX Medical and Caris in the UK and Nordic countries. Credit: PawelKacperek / Shutterstock.

EDX Medical Group has announced a distribution partnership with Caris Life Sciences, a provider of next-generation AI TechBio and precision medicine from the US, for the UK and Nordic countries.

The collaboration will focus on the exclusive distribution of Caris’ advanced molecular profiling services to enhance cancer treatment decisions through personalised medicine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Caris’ molecular profiling services utilise DNA, RNA, and protein assessments to create a comprehensive molecular blueprint of a patient’s cancer. This blueprint aids physicians in identifying tailored treatment options.

The agreement stipulates a minimum three-year exclusive partnership between EDX Medical and Caris in the UK and Nordic countries, including Sweden, Denmark, Norway, and Finland.

The services will be available immediately, with plans to expand to additional regions and products.

EDX Medical founder Sir Chris Evans said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of cancer for patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.”

Caris Life Sciences’ molecular profiling services, which include solid tumour and liquid biopsy analysis, as well as AI solutions will be distributed by EDX Medical.

Caris Life Sciences president Dr David Spetzler said: “Caris is pleased to partner with EDX Medical to distribute our molecular profiling services within the UK and Nordic countries.

“This collaboration aligns with Caris’ goal of enabling clinicians worldwide to make the best-individualised treatment choices for their patients and ultimately helping to improve patient outcomes.”

In June 2024, EDX Medical announced the launch of its diagnostic tool in the UK to identify patients’ risk of developing hereditary cancer.